Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
Publication
, Journal Article
George, DJ
Published in: Clin Adv Hematol Oncol
July 2019
Duke Scholars
Published In
Clin Adv Hematol Oncol
ISSN
1543-0790
Publication Date
July 2019
Volume
17
Issue
7
Start / End Page
382 / 385
Location
United States
Related Subject Headings
- Zoledronic Acid
- Prostatic Neoplasms
- Prostate-Specific Antigen
- Prednisone
- Prednisolone
- Phenylthiohydantoin
- Oncology & Carcinogenesis
- Nitriles
- Neoplasm Metastasis
- Male
Citation
APA
Chicago
ICMJE
MLA
NLM
George, D. J. (2019). Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy. Clin Adv Hematol Oncol, 17(7), 382–385.
George, Daniel J. “Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.” Clin Adv Hematol Oncol 17, no. 7 (July 2019): 382–85.
George DJ. Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy. Clin Adv Hematol Oncol. 2019 Jul;17(7):382–5.
George, Daniel J. “Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.” Clin Adv Hematol Oncol, vol. 17, no. 7, July 2019, pp. 382–85.
George DJ. Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy. Clin Adv Hematol Oncol. 2019 Jul;17(7):382–385.
Published In
Clin Adv Hematol Oncol
ISSN
1543-0790
Publication Date
July 2019
Volume
17
Issue
7
Start / End Page
382 / 385
Location
United States
Related Subject Headings
- Zoledronic Acid
- Prostatic Neoplasms
- Prostate-Specific Antigen
- Prednisone
- Prednisolone
- Phenylthiohydantoin
- Oncology & Carcinogenesis
- Nitriles
- Neoplasm Metastasis
- Male